All In Biotech

Drug Trial Radar · NCT05418348

Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

A Phase 1, Randomized, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules at Steady State in Healthy Male and Female Subjects

Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Aug 26, 2021

Primary completion

Feb 17, 2022

Study completion Feb 24, 2022

Sponsor

Lead sponsor
Grace Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single center, randomized, two-period crossover study in healthy male and female subjects designed to evaluate the relative bioavailability (BA) and safety at steady state of two formulations of nimodipine: GTX 104 (nimodipine for intravenous \[IV\] infusion; test formulation) and nimodipine oral capsules, RS (reference formulation).

Conditions

  • Aneurysmal Subarachnoid Hemorrhage

Interventions

  • GTX-104Drug

    new formulation of nimodipine injection for IV infusion

  • Nimodipine CapsulesDrug

    Nimodipine capsules (reference formulation)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax Day 1Time frame: Day 1 for the first dose (8:00 AM dose)
  2. AUC (AUCDay 3, 0-24hr)Time frame: Day 3 from 8:00 AM to 8:00 AM from 0 to 24 hr

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Unit

    Montreal, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.